Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A

Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A

SSZSE:300452
11.38
CNY
-0.08
(-0.70%)
0.69EPS
18.26P/E
3.11BMarket Cap
Apr 29Next Earn

Total Valuation

CNY

As of September 30, 2026, Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A carries a market capitalization of 3.11B, placing it among publicly traded companies globally. Its enterprise value stands at 2.65B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.11B
Enterprise Value2.65B

Important Dates

Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A's next confirmed earnings release is scheduled for April 29, 2027.

Earnings Date4/29/2027

Share Statistics

As of September 30, 2026, Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A has 234.46M shares outstanding.

Shares Outstanding234.46M

Valuation Ratios

As of September 30, 2026, Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 18.26. The price-to-sales ratio is 3.05, and the price-to-book ratio stands at 2.92.

PE Ratio18.26
PS Ratio3.05
PB Ratio2.92
P/TBV Ratio3.16

Enterprise Valuation

As of September 30, 2026, Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A trades at an EV/EBITDA multiple of 13.82 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.61 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.82 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.65B versus a market cap of 3.11B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.61
EV / EBITDA13.82
EV / EBIT13.82

Financial Position

As of September 30, 2026, Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A maintains a current ratio of 3.91, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 30.70, indicating elevated leverage, while an interest coverage ratio of 13.87 demonstrates strong ability to service its debt obligations.

Current Ratio3.91
Quick Ratio2.78
Debt / Equity30.70
Debt / EBITDA1.81
Interest Coverage13.87

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 897,980.38 in revenue per employee across its workforce of 1,130.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee897,980.38
Employee Count1,130.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A recorded 24.88M in income tax expense. That works out to an effective tax rate of 13.00, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 191.40M, leaving 169.37M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax24.88M
Effective Tax Rate13.00

Stock Price Statistics

CNY

As of the close on November 17, 2026, Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A's stock has declined approximately 18.42% over the past 52 weeks. The 50-day moving average sits at 12.46, while the 200-day moving average is 13.41.

52-Week Price Change-18.42%
50-Day Moving Average12.46
200-Day Moving Average13.41

Income Statement

CNY

Over the twelve months ended September 30, 2026, Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A generated 1.01B in revenue and converted that into 169.37M in net income, yielding earnings per share of 0.69. EBITDA reached 191.64M, while operating income came in at 201.77M.

Revenue1.01B
Gross Profit318.33M
Operating Income201.77M
Pretax Income191.40M
Net Income169.37M
EBITDA191.64M
EBIT191.64M
Earnings Per Share (EPS)0.69

Balance Sheet

CNY

As of September 30, 2026, Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A holds 876.35M in cash and equivalents against 347.47M in total debt, resulting in a net debt position of 144.83M. Total book value stands at 1.06B, with working capital of 916.51M providing operational flexibility.

Cash & Cash Equivalents876.35M
Total Debt347.47M
Net Debt144.83M
Equity (Book Value)1.06B
Book Value Per Share4.54
Working Capital916.51M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-65.09M

Margins

Over the twelve months ended September 30, 2026, Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A posted a gross margin of 31.37, reflecting its pricing power and cost economics. The operating margin of 19.88 and net profit margin of 16.69 provide insight into operational efficiency.

Gross Margin31.37
Operating Margin19.88
Pretax Margin18.86
Profit Margin16.69
EBITDA Margin18.89

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A paid dividends of 0.31 per share. The dividend payout ratio of 44.70 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.04, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A shareholders.

Dividend Per Share0.31
Payout Ratio44.70
Shareholder Yield1.04

Stock Splits

Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A's most recent stock split took place on May 26, 2022 with a 10:13 split ratio.

Last Split Date5/26/2022
Split Ratio10:13

Scores

As of September 30, 2026, Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A has an Altman Z-Score of 4.86, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.86